 | Second COVID-19 trial paused within 24 hours over safety concernsThe Covid-19 treatment studied in the paused trial was based on an effective antibody Lilly found in a recovered patient. |
 | Oxford and AstraZeneca resume coronavirus vaccine trialIn a statement, the university confirmed the restart across all of its U.K. clinical trial sites after regulators gave the go-ahead following the pause on Sunday. |
 | Oxford vaccine trial stopped after volunteer developed neurological symptoms: AstraZenecaThe study participant in late-stage testing reported symptoms consistent with transverse myelitis, a rare inflammation of the spinal cord, said company spokesman Matthew Kent. |
 | 'Reviewing situation': Serum Institute pauses COVID-19 vaccine trials in India after DCGI noticeThe drug regulator's move comes after AstraZeneca, which is developing the vaccine candidate against COVID-19 with researchers of Oxford University |
 | Mysuru: Oxford vaccine trials halted in UK, but JSS institute's trials going fineHowever, speaking to TNIE, B Suresh, Pro Chancellor of JSS AHER, said that so far, none among their 32 volunteers have reported any adverse reactions and all are doing fine. |
 | India will continue Oxford vaccine trial, says Serum Institute after illness in volunteer pauses trial abroadSerum Institute of India, under whose aegis the vaccine is to be being tried on 1,600 participants across 17 centres, said that trials in India will continue, irrespective of the latest development. |
 | AstraZeneca pauses Oxford COVID-19 vaccine trial after volunteer's unexplained illnessAstraZeneca is one of nine companies currently in late-stage Phase 3 trials for their vaccine candidates. In the US, the company began enrolling 30,000 volunteers across dozens of sites on August 31. |
 | UNICEF to lead global procurement, supply of COVID vaccines; Australia to fund two potential candidatesUNICEF is the world's largest single vaccine buyer, procuring more than 2 billion doses of various vaccines annually for routine immunisation and outbreak response on behalf of nearly 100 countries. |
 | AstraZeneca's COVID-19 vaccine reaches phase 3 clinical trials in US, says Donald TrumpThe UK-based global biopharmaceutical company AstraZeneca is leading the trial as regulatory sponsor. |
 | Phase two trials of Oxford's COVID vaccine start in Mysuru hospitalThe ICMR will collect 100 samples from across the country for further study and look into modifications. |
 | If everything goes well India would get COVID-19 vaccine by year-end: Harsh VardhanThree COVID-19 vaccine candidates, including two indigenous ones, are in different phases of development in India. |
 | Australia to manufacture 'promising' COVID-19 vaccine, free distribution for citizensPrime Minister Scott Morrison said that Australia had reached a deal with Swedish-British pharmaceutical company AstraZeneca to receive the COVID-19 vaccine it is developing with Oxford University. |
 | Mexico to produce Oxford COVID-19 vaccine pending results, approvalProduction of the vaccine in Mexico and Argentina would allow for distribution throughout Latin America, except for Brazil, which had already reached its own agreement with the drug maker. |
 | Hotspots Mumbai, Pune to help test Oxford COVID-19 vaccine efficacy: Serum Institute of IndiaBy end of August, between 4,000 to 5,000 people in Pune and Mumbai will be injected with the vaccine as part of trials that are scheduled to last over two months, SII said. |
 | COVID-19 vaccine to cost Rs 1,000 per dose, says Serum Institute CEOAdra Poonawalla told TNIE that the mass production of vaccine against the COVID-19 will start in the first quarter of next year while the human trials in India will start next month. |
